Titre : Ligaments longitudinaux

Ligaments longitudinaux : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Ligaments longitudinaux : Questions médicales les plus fréquentes", "headline": "Ligaments longitudinaux : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Ligaments longitudinaux : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-06", "dateModified": "2025-05-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Ligaments longitudinaux" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Ligaments articulaires", "url": "https://questionsmedicales.fr/mesh/D008023", "about": { "@type": "MedicalCondition", "name": "Ligaments articulaires", "code": { "@type": "MedicalCode", "code": "D008023", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A10.165.669.514" } } }, "about": { "@type": "MedicalCondition", "name": "Ligaments longitudinaux", "alternateName": "Longitudinal Ligaments", "code": { "@type": "MedicalCode", "code": "D017846", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Yoshiharu Kawaguchi", "url": "https://questionsmedicales.fr/author/Yoshiharu%20Kawaguchi", "affiliation": { "@type": "Organization", "name": "Department of Orthopaedic Surgery, Toyama University, Toyama, Japan." } }, { "@type": "Person", "name": "Toshitaka Yoshii", "url": "https://questionsmedicales.fr/author/Toshitaka%20Yoshii", "affiliation": { "@type": "Organization", "name": "Department of Orthopaedic Surgery, Tokyo Medical and Dental University, Tokyo, Japan." } }, { "@type": "Person", "name": "Takeo Furuya", "url": "https://questionsmedicales.fr/author/Takeo%20Furuya", "affiliation": { "@type": "Organization", "name": "Department of Orthopedic Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo Ward, Chiba 260-8670, Japan." } }, { "@type": "Person", "name": "Masahiko Takahata", "url": "https://questionsmedicales.fr/author/Masahiko%20Takahata", "affiliation": { "@type": "Organization", "name": "Department of Orthopedic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan." } }, { "@type": "Person", "name": "Shiro Imagama", "url": "https://questionsmedicales.fr/author/Shiro%20Imagama", "affiliation": { "@type": "Organization", "name": "Department of Orthopedics, Nagoya University Graduate School of Medicine, Nagoya, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Decoding the genetic links between serum lipidomic profile, amino acid biomarkers, and programmed cell death protein-1/programmed cell death-ligand-1.", "datePublished": "2023-07-27", "url": "https://questionsmedicales.fr/article/37498324", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00262-023-03501-8" } }, { "@type": "ScholarlyArticle", "name": "C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction.", "datePublished": "2024-06-04", "url": "https://questionsmedicales.fr/article/38893521", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/molecules29112646" } }, { "@type": "ScholarlyArticle", "name": "The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.", "datePublished": "2023-03-25", "url": "https://questionsmedicales.fr/article/36966236", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41416-023-02218-w" } }, { "@type": "ScholarlyArticle", "name": "Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells.", "datePublished": "2023-03-06", "url": "https://questionsmedicales.fr/article/36889184", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.molimm.2023.02.007" } }, { "@type": "ScholarlyArticle", "name": "Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.", "datePublished": "2023-02-27", "url": "https://questionsmedicales.fr/article/36848319", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cncr.34683" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Tissus", "item": "https://questionsmedicales.fr/mesh/D014024" }, { "@type": "ListItem", "position": 3, "name": "Tissu conjonctif", "item": "https://questionsmedicales.fr/mesh/D003238" }, { "@type": "ListItem", "position": 4, "name": "Ligaments", "item": "https://questionsmedicales.fr/mesh/D008022" }, { "@type": "ListItem", "position": 5, "name": "Ligaments articulaires", "item": "https://questionsmedicales.fr/mesh/D008023" }, { "@type": "ListItem", "position": 6, "name": "Ligaments longitudinaux", "item": "https://questionsmedicales.fr/mesh/D017846" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Ligaments longitudinaux - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Ligaments longitudinaux", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Ligaments longitudinaux", "description": "Comment diagnostiquer une lésion des ligaments longitudinaux ?\nQuels tests sont utilisés pour évaluer la fonction des ligaments longitudinaux ?\nQuels signes cliniques indiquent une atteinte des ligaments longitudinaux ?\nLes examens d'imagerie sont-ils toujours nécessaires ?\nQuelle est l'importance de l'historique médical dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D017846?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Ligaments longitudinaux", "description": "Quels sont les symptômes d'une lésion ligamentaire ?\nLa douleur est-elle toujours présente avec une lésion des ligaments ?\nComment la douleur des ligaments longitudinaux se manifeste-t-elle ?\nY a-t-il des symptômes associés à une inflammation des ligaments ?\nLes symptômes varient-ils selon l'âge ?", "url": "https://questionsmedicales.fr/mesh/D017846?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Ligaments longitudinaux", "description": "Comment prévenir les blessures des ligaments longitudinaux ?\nLes activités sportives augmentent-elles le risque de lésion ?\nEst-il important de maintenir un poids santé pour la prévention ?\nLes étirements réguliers aident-ils à prévenir les blessures ?\nLa formation sur la posture est-elle utile ?", "url": "https://questionsmedicales.fr/mesh/D017846?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Ligaments longitudinaux", "description": "Quels traitements sont recommandés pour les lésions ligamentaires ?\nLa chirurgie est-elle nécessaire pour les lésions des ligaments longitudinaux ?\nQuels exercices sont bénéfiques pour renforcer les ligaments ?\nLes traitements alternatifs sont-ils efficaces ?\nCombien de temps dure la récupération après une lésion ligamentaire ?", "url": "https://questionsmedicales.fr/mesh/D017846?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Ligaments longitudinaux", "description": "Quelles complications peuvent survenir après une lésion ligamentaire ?\nLes lésions ligamentaires peuvent-elles entraîner des problèmes neurologiques ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles plus fréquentes chez les personnes âgées ?\nLes complications peuvent-elles être évitées ?", "url": "https://questionsmedicales.fr/mesh/D017846?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Ligaments longitudinaux", "description": "Quels sont les principaux facteurs de risque pour les lésions ligamentaires ?\nLe manque d'exercice est-il un facteur de risque ?\nLes antécédents de blessures augmentent-ils le risque ?\nLes conditions médicales préexistantes influencent-elles le risque ?\nLe tabagisme est-il un facteur de risque pour les lésions ligamentaires ?", "url": "https://questionsmedicales.fr/mesh/D017846?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une lésion des ligaments longitudinaux ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un examen clinique et des imageries comme l'IRM ou la radiographie sont utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer la fonction des ligaments longitudinaux ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de flexibilité et de stabilité vertébrale sont souvent réalisés." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une atteinte des ligaments longitudinaux ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Douleur, raideur et limitation des mouvements de la colonne vertébrale peuvent indiquer une atteinte." } }, { "@type": "Question", "name": "Les examens d'imagerie sont-ils toujours nécessaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, mais ils sont recommandés si les symptômes persistent ou s'aggravent." } }, { "@type": "Question", "name": "Quelle est l'importance de l'historique médical dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'historique aide à identifier des blessures antérieures ou des maladies pouvant affecter les ligaments." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une lésion ligamentaire ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Douleur, gonflement, et difficulté à bouger la colonne vertébrale sont fréquents." } }, { "@type": "Question", "name": "La douleur est-elle toujours présente avec une lésion des ligaments ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, certaines lésions peuvent être asymptomatiques au début." } }, { "@type": "Question", "name": "Comment la douleur des ligaments longitudinaux se manifeste-t-elle ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être localisée ou irradier vers d'autres zones, comme les jambes." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés à une inflammation des ligaments ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, rougeur, chaleur et gonflement peuvent accompagner l'inflammation." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent présenter des symptômes plus prononcés en raison de l'usure." } }, { "@type": "Question", "name": "Comment prévenir les blessures des ligaments longitudinaux ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un bon échauffement, des exercices de renforcement et une bonne posture aident à prévenir." } }, { "@type": "Question", "name": "Les activités sportives augmentent-elles le risque de lésion ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les sports à fort impact ou de contact peuvent augmenter le risque de lésion." } }, { "@type": "Question", "name": "Est-il important de maintenir un poids santé pour la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un poids santé réduit la pression sur la colonne vertébrale et les ligaments." } }, { "@type": "Question", "name": "Les étirements réguliers aident-ils à prévenir les blessures ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des étirements réguliers améliorent la flexibilité et réduisent le risque de blessures." } }, { "@type": "Question", "name": "La formation sur la posture est-elle utile ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une bonne formation sur la posture peut prévenir les douleurs et les blessures." } }, { "@type": "Question", "name": "Quels traitements sont recommandés pour les lésions ligamentaires ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Repos, physiothérapie, et médicaments anti-inflammatoires sont souvent prescrits." } }, { "@type": "Question", "name": "La chirurgie est-elle nécessaire pour les lésions des ligaments longitudinaux ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elle est rare et réservée aux cas graves où d'autres traitements échouent." } }, { "@type": "Question", "name": "Quels exercices sont bénéfiques pour renforcer les ligaments ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des exercices de renforcement et d'étirement ciblant le dos et le tronc sont recommandés." } }, { "@type": "Question", "name": "Les traitements alternatifs sont-ils efficaces ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certaines thérapies comme l'acupuncture peuvent soulager la douleur, mais les preuves varient." } }, { "@type": "Question", "name": "Combien de temps dure la récupération après une lésion ligamentaire ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La récupération peut prendre de quelques semaines à plusieurs mois selon la gravité." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après une lésion ligamentaire ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs chroniques, une instabilité vertébrale et des limitations fonctionnelles peuvent survenir." } }, { "@type": "Question", "name": "Les lésions ligamentaires peuvent-elles entraîner des problèmes neurologiques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une compression nerveuse due à une lésion peut provoquer des symptômes neurologiques." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent limiter les activités quotidiennes et affecter le bien-être général." } }, { "@type": "Question", "name": "Les complications sont-elles plus fréquentes chez les personnes âgées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de complications augmente avec l'âge en raison de la dégénérescence des tissus." } }, { "@type": "Question", "name": "Les complications peuvent-elles être évitées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines peuvent être évitées par une réhabilitation appropriée et un suivi médical régulier." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque pour les lésions ligamentaires ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, le surpoids, et la pratique de sports à risque augmentent les chances de lésion." } }, { "@type": "Question", "name": "Le manque d'exercice est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire peut affaiblir les ligaments et augmenter le risque de blessure." } }, { "@type": "Question", "name": "Les antécédents de blessures augmentent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des blessures antérieures peuvent rendre les ligaments plus vulnérables à de nouvelles lésions." } }, { "@type": "Question", "name": "Les conditions médicales préexistantes influencent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme l'arthrite peuvent affaiblir les ligaments et augmenter le risque." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque pour les lésions ligamentaires ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut affecter la circulation sanguine et retarder la guérison des tissus." } } ] } ] }

Sources (10000 au total)

Decoding the genetic links between serum lipidomic profile, amino acid biomarkers, and programmed cell death protein-1/programmed cell death-ligand-1.

Disruptions in lipid metabolism and amino acids have been increasingly linked to resistance to immunotherapy. However, the underlying mechanisms by which dysregulated serum lipid metabolism and amino ... To elucidate the potential associations between lipid metabolism, amino acids, and PD-1/PD-L1, we employed the powerful Mendelian randomization (MR) method, leveraging large-scale genome-wide associat... In the present MR study, we identified a noteworthy negative association between alanine and PD-1 expression, implicating a regulatory role for alanine metabolism in modulating the immune response to ... These findings provided new insights into the role of lipid metabolism as well as amino acids in regulating PD-1/PD-L1, suggesting that strategies targeting lipid and amino acid metabolisms may have t...

C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction.

The PD-1/PD-L1 complex is an immune checkpoint responsible for regulating the natural immune response, but also allows tumors to escape immune surveillance. Inhibition of the PD-1/PD-L1 axis positivel...

The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.

Tumour-infiltrating lymphocytes (TILs) represent a robust biological prognostic biomarker in triple-negative breast cancer (TNBC); however, the contribution of different subsets of immune cells is unc... In total, 259 patients with Stage I-III TNBC were reviewed. The density of sTILs along with the presence of total (t), stromal (s), and intratumoral (i) CD8... All immune markers were positively correlated with each other (P < 0.05). In the multivariate analysis, sTILs (P = 0.046), tCD8... In addition to sTILs, inclusion of tCD8...

Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells.

Activation of PD-1 by anchoring it to Antigen Receptor (AR) components or associated co-receptors represents an attractive approach to treat autoimmune conditions. In this study, we provide evidence t...

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.

The availability of agents targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has transformed treatment of advanced and/or metastatic non-small ce...

EXPRESSION OF PROGRAMMED CELL DEATH RECEPTOR IN ENDOMETRIAL CANCER PATIENTS WITH METABOLIC DISORDERS.

To study the expression of the programmed cell death receptor (PD-1) and its ligand (PD-L1) by immunocompetent cells in endometrial cancer patients with metabolic disorders.... Populations and subpopulations of lymphocytes were analyzed by flow cytometry. Antibodies against CD279 were used to detect PD-1 on the CD4+ and CD8+ T cells. Antibodies against CD14 and CD274 were us... In patients with severe metabolic disorders, the expression of PD-1 on CD8+ and CD4+ lymphocytes and the expression of the corresponding PD-L1 on CD14+ cells before treatment and after radiation thera... Theincreased expression of PD-1 and PD-L1 receptors by immunocompetent cells can be considered a new prognostic marker in endometrial cancer patients with morbid obesity....

Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China.

Programmed death receptor 1 (PD-1) inhibition has shown durable response and mild adverse events (AEs) in adult malignancies. However, data on the clinical activity of PD-1 inhibition in pediatric pat... We conducted a real-world, multi-institutional, retrospective analysis of pediatric malignancies treated with PD-1 inhibitor-based regimens. The primary endpoints were objective response rate (ORR) an... A total of 93 and 109 patients were evaluated for efficacy and safety, respectively. For all efficacy-evaluable patients, PD-1 inhibitor monotherapy, combined chemotherapy, combined histone deacetylas... This largest retrospective analysis demonstrate that PD-1 inhibitor-based regimens are potentially effective and tolerable in pediatric malignancies. Our findings provide references for future clinica...

Combined chemoradiotherapy and programmed cell death-ligand 1 blockade leads to changes in the circulating T-cell receptor repertoire of patients with non-small-cell lung cancer.

Combined chemoradiotherapy (CRT) and programmed cell death-ligand 1 (PD-L1) blockade is a new care standard for unresectable stage III non-small-cell lung cancer (NSCLC). Although this consolidation t...